When your company has a product in development, whether drug, device or biotech, what you can — and can’t — say about it is tightly regulated by the FDA.
At the same time, the SEC requires that information of material value to investors be properly disclosed to them.
Of course, this SEC requirement involves exactly the same products you have in your pipeline, the ones that the FDA wants you to be very careful about discussing.
This management report will tell you how to balance these seemingly contradictory demands and how to handle all the forms “communication” takes today — from tweets to talking points, from press releases to the slides investors see on a conference call. You will learn:
The specific laws and regulations the FDA and SEC must enforce;
6 dos and 6 don'ts for speaking publicly about a product in development;
4 dos and 3 don'ts when talking with analysts and investors;
Examples from case studies about communication that resulted in FDA enforcement actions, SEC penalties, and investor lawsuits;
And much more.
With Managing Product Pipeline Communications you’ll be able to confidently account for the various perspectives — regulators on both sides, investors and the general public — and ensure that the right people get the information they should from you every time.
Anyone who might be talking to people outside the company (general public, the media, investors) about a product
Save money with a license agreement allowing significant numbers of users access to an electronic version of this book. For multi-user access to multiple titles, FDAnews offers the FDAnews Online Library – a personalized collection of FDAnews publications that is fully searchable. Contact Customer Service for a quote or more information.
Not satisfied with your publication? For the PDF version, you must notify FDAnews within 24 hours of receipt of purchase and we will refund 100 percent of your purchase price.